中国医学创新2024，Vol.21Issue(10)：179-183,5.DOI:10.3969/j.issn.1674-4985.2024.10.041
依达拉奉右莰醇治疗缺血性脑卒中的研究进展
Research Progress of Edaravone Dexborneol in the Treatment of Ischemic Stroke
席娅琳 1汪临华 1鹿树军1
作者信息
- 1. 滨州医学院附属医院神经内科 山东 滨州 256600
- 折叠
摘要
Abstract
Ischemic stroke is a common type of cerebrovascular disease that can lead to advanced cognitive and motor deficits and even death.The treatment of ischemic stroke mainly includes early thrombolysis and neuroprotection.However,the clinical efficacy of neuroprotective agents remains to be verified,and most neuroprotective agents have not yet received useful evidence.Edaravone Dexborneol(ED),a new dual-target neuroprotective agent,can inhibit the expression of inducible nitric oxide synthase(iNOS)and tumor necrosis factor-α(TNF-α),reduce the level of peroxynitrite anion(ONOO-),and improve the symptoms of nerve injury,dysfunction,and activity disorder caused by ischemic stroke.This article will review the mechanism of ED and its application development,and prospect the clinical application of ED,so as to provide guidance for subsequent medication.关键词
缺血性脑卒中/自由基清除剂/神经保护剂/依达拉奉右莰醇Key words
Ischemic stroke/Free radical scavenger/Neuroprotective agent/Edaravone Dextrogenol引用本文复制引用
席娅琳,汪临华,鹿树军..依达拉奉右莰醇治疗缺血性脑卒中的研究进展[J].中国医学创新,2024,21(10):179-183,5.
